US’ Pfizer aims to produce 10-20 mln doses of coronavirus vaccine by end of 2020

Published: Updated:

Pfizer aims to make 10-20 million doses of a coronavirus vaccine it is developing with Germany’s BioNtech by the end of 2020 for possible emergency use depending on trial results, the US drug maker’s vaccines head said on Thursday.

“Of course, we need to see and wait to see how the vaccine’s efficacy and safety is demonstrated, hopefully in the coming months,” Nanette Cocero, the global head of Pfizer Vaccines, said on a conference call.

Visit our dedicated coronavirus site here for all the latest updates.

“But assuming that is demonstrated, we are looking to ramp up manufacturing rather quickly to have around 10 to 20 mln doses by the end of this year, which are expected to then of course be used in an emergency type of setting.”

Also, US President Donald Trump said on Thursday the United States plans to accelerate the development of a coronavirus vaccine, an effort that has been dubbed “Operation Warp Speed.”

Trump, speaking to reporters in the Oval Office, said he is in overall charge of the project aimed at finding a vaccine for the virus as quickly as possible.

“Whatever you can humanly do, we’re going to have,” he said. “I hope we’re going to have a vaccine and we’re going to fast-track it like you’ve never seen.”

Asked who is in charge of “Operation Warp Speed,” Trump said, “You know who’s in charge of it? I am.”
“I’m the one who gets blamed,” he added.

Government agencies and the military will team up with the private sector with the goal of having 100 million doses of the coronavirus vaccine ready by the end of 2020. Executives and other experts have previously suggested that clinical trials to guarantee a vaccine is safe and effective could take longer, at a minimum of 12 to 18 months.

The Biomedical Advanced Research and Development Authority, or BARDA, recently announced nearly $1 billion in support of vaccine manufacturing efforts by Moderna and Johnson & Johnson.

As the country races to find a vaccine for the potentially deadly virus it is also working toward treatments, with early data showing on Wednesday that Gilead Sciences Inc’s experimental antiviral drug remdesivir helped patients recover more quickly from the illness caused by the coronavirus.

Read more:

UN launches global push to accelerate production of coronavirus vaccine, treatments

Coronavirus: WHO declines comment on remdesivir in COVID-19, hopes for best

Hydroxychloroquine not very effective in treating coronavirus patients, says study